In a few weeks’ time NICE – England and Wales’s drugs cost regulator – is set to make it a little easier for drugs to be approved for NHS use on cost grounds. Specifically, the cost ceiling is going to rise. This ceiling – the so-called “QALY threshold” – is actually a range. And that range is going to go up from £20 – […]
Novo Nordisk Foundation announced it had awarded DKK 11.8 billion (€1.6 billion) during 2025 to support more than 2,200 projects aimed at improving people’s health and the sustainability of society and the planet. The projects cover the full range of the Foundation’s grant-giving areas, including key topics such as cardiometabolic diseases, antimicrobial resistance, the development of more resilient and climate-friendly […]
Many more women are taking GLP-1 weight loss drugs than men. That’s the fascinating take-out from a recent analysis of more than 100,000 people taking the drugs privately in the UK, by a think tank called The Health Foundation. It wasn’t just a small weighting: for every man taking drugs GLP-1s like Wegovy and Mounjaro privately in the UK, four women are doing so. Now we can all guess why this is the […]
Hansa Biopharma’s Biologics License Application (BLA) for imlifidase accepted by the FDA Hansa Biopharma announced that its Biologics License Application (BLA) for imlifidase has been accepted by the U.S. Food and Drug Administration (FDA). The BLA submission for imlifidase is supported by the previously communicated highly statistically significant outcome of the pivotal U.S. Phase 3 […]
Let’s talk antibiotics. Specifically: Is our policy about how we might use new antibiotics, wrong? A little on background first. Resistance to existing antibiotics is growing and the pipeline of new ones is thin. If we don’t get our act together – so the warnings go – we’ll sleepwalk into a post-antibiotic apocalypse, where surgery is a nightmare and a scratch could be deadly. Current thinking is that […]
